Austin, TX Clinical Trials Report — April 2026

For Austin residents considering participation in clinical research, April 2026 presents both urgent opportunities and new avenues for contribution. Currently, 652 clinical trials are recruiting across 395 research facilities in Austin, offering a wide range of options for patients and healthy volunteers alike.

Act Fast: Trials Closing Soon

A significant number of trials in Austin are nearing their enrollment deadlines. Within the next 90 days, 35 clinical trials will be closing. This urgency is particularly relevant for those interested in conditions such as idiopathic hypersomnia, obesity, and being overweight, each with 2 trials concluding soon. Other conditions with trials closing include:

• Acute gouty arthritis
• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Acute limb ischemia
• Advanced solid tumor
• Amyotrophic lateral sclerosis
• Antiphospholipid syndrome (APS)

For healthy volunteers, time is also of the essence. Of the trials closing within the next 90 days, 5 are still actively seeking participants without specific health conditions. Individuals interested in these opportunities should explore them promptly.

New Research Opportunities in Austin

This month, Austin saw the opening of 8 new clinical trials. This marks a decrease compared to the 13 trials that launched in March 2026, and it is the lowest number of new openings in the past 6 months. Despite this, these new studies bring important advancements to the city's research landscape.

Among the new trials, several notable studies are now recruiting:

• Priovant Therapeutics, Inc. is sponsoring NCT07532603, "A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris." This Phase 2/3 study aims to enroll 342 participants to evaluate the safety and efficacy of oral brepocitinib for lichen planopilaris.
• Caliway Biopharmaceuticals Co., Ltd. is launching NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )." This Phase 3, randomized, double-blinded, placebo-controlled study will assess CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Zenflow, Inc. is initiating NCT07538622, "Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry." This registry aims to collect real-world data on the Zenflow Spring System, a minimally invasive treatment for BPH, tracking its performance in 300 participants.

New trials this month are exploring a range of conditions, including benign prostatic hyperplasia (BPH), castration-resistant prostate cancer (CRPC), ER+, HER2- breast cancer, and studies related to exercise intensity, fear conditioning, and fear extinction. There is also a new trial specifically for healthy adult participants. Of the new studies, 4 are drug trials, 2 are device trials, 1 is a behavioral trial, and 1 is categorized as other. Academic institutions, including the University of Texas at Austin and Vanderbilt University Medical Center, are sponsoring 4 of the new trials, with industry sponsors like IDEAYA Biosciences, Caliway Biopharmaceuticals Co., Ltd., Zenflow, Inc., and Priovant Therapeutics, Inc. sponsoring the other 4.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical research. This month, 2 of the 8 new trials are accepting healthy volunteers. Overall, Austin has 60 clinical trials currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements.

Austin's Leading Research Facilities

Austin is home to a robust network of research facilities that are actively conducting clinical trials. These institutions are key destinations for individuals seeking to participate in medical research:

• Dell Children's Medical Center of Central Texas (37 trials)
• University of Texas at Austin (24 trials)
• Research Site (23 trials)
• The University of Texas at Austin (17 trials)
• Texas Cardiac Arrhythmia Research Foundation (12 trials)
• Dell Children's Medical Center (11 trials)
• GSK Investigational Site (10 trials)
• Austin Retina Associates (10 trials)
• NEXT Austin (10 trials)
• Austin Heart (9 trials)
• FutureSearch Trials of Neurology (9 trials)
• Texas Oncology - Central/South Texas (9 trials)

These facilities cover a broad spectrum of medical research, from pediatric care at Dell Children's Medical Center, to academic research at the University of Texas at Austin, and specialized studies in cardiology, ophthalmology, neurology, and oncology at their respective centers.

Who Can Participate? Eligibility and Demographics

Participation in clinical trials is open to a diverse range of individuals. Among the 8 new trials launched this month, 1 includes children, 1 is specifically for female participants, and 1 is for male participants. Additionally, 5 of the new trials are designed to include older adults, ensuring that various age groups have opportunities to contribute to medical science.

Expanding Your Search: Texas-Wide Options

While Austin offers a significant number of clinical trial opportunities, individuals in Texas may also find options in other major cities. Nearby communities with active trials include Houston (26 trials), Dallas (15 trials), San Antonio (15 trials), Fort Worth (4 trials), Galveston (3 trials), Irving (2 trials), Plano (2 trials), and Lewisville (1 trial).

As Austin's research community continues to grow, the coming months will bring further opportunities for residents to engage with cutting-edge medical advancements and contribute to the development of new treatments and therapies.